Sight Sciences Q1 revenue $17.5M (-9% YoY); reaffirms FY25 guidance $70-75M; lowers expense guide

Sight Sciences, Inc.

2025-Q1 EPS reported -$0.28 revenue$17,508,000

Total revenue $17.5M, down 9% YoY; Surgical Glaucoma $17.1M (-6% YoY); Dry Eye $0.4M (-60% YoY).
Gross margin 86% flat YoY; net loss $14.2M ($0.28 loss per share) vs $16.3M loss in prior year.
Reaffirms FY25 revenue guidance $70-75M (decline 6-12% YoY); lowers adjusted op ex guide to $101-105M.
Tariffs on China-made products seen adding $3.5-4.5M to 2025 COGS; impact larger in H2 2025.
Launched OMNI Edge with TruSync technology at ASCRS April 2025; TearCare reimbursement not assumed in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.